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Background: Research into the methods used in the design, conduct, analysis, and reporting of clinical trials is
essential to ensure that effective methods are available and that clinical decisions made using results from trials are
based on the best available evidence, which is reliable and robust.
Methods: An on-line Delphi survey of 48 UK Clinical Research Collaboration registered Clinical Trials Units (CTUs) was
undertaken. During round one, CTU Directors were asked to identify important topics that require methodological
research. During round two, their opinion about the level of importance of each topic was recorded, and during round
three, they were asked to review the group’s average opinion and revise their previous opinion if appropriate. Direct
reminders were sent to maximise the number of responses at each round. Results are summarised using descriptive
methods.
Results: Forty one (85%) CTU Directors responded to at least one round of the Delphi process: 25 (52%) responded in
round one, 32 (67%) responded in round two, 24 (50%) responded in round three. There were only 12 (25%) who
responded to all three rounds and 18 (38%) who responded to both rounds two and three. Consensus was achieved
amongst CTU Directors that the top three priorities for trials methodological research were ‘Research into methods to
boost recruitment in trials’ (considered the highest priority), ‘Methods to minimise attrition’ and ‘Choosing appropriate
outcomes to measure’. Fifty other topics were included in the list of priorities and consensus was reached that two
topics, ‘Radiotherapy study designs’ and ‘Low carbon trials’, were not priorities.
Conclusions: This priority setting exercise has identified the research topics felt to be most important to the key
stakeholder group of Directors of UKCRC registered CTUs. The use of robust methodology to identify these priorities
will help ensure that this work informs the trials methodological research agenda, with a focus on topics that will have
most impact and relevance.
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Clinical trials are studies conducted in patients to evalu-
ate the potential benefits and harms of interventions
such as drugs and non-pharmaceutical treatments. Clin-
ical trials provide evidence to inform and improve pa-
tient care, and the randomised trial is considered at the
upper level of the hierarchy of evidence (see reference
[1] for example) for effectiveness studies. Methodological
research in the field of clinical trials can lead to the
development and progress of methodology, as well* Correspondence: cat1@liv.ac.uk
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The United Kingdom Clinical Research Collaboration
(UKCRC) has a network of registered Clinical Trials
Units (CTUs) which have provided evidence to an inter-
national panel of experts of their capability to coordinate
multi-centre clinical trials (that is, having overall respon-
sibility for the design, development, recruitment, data
management, publicity and analysis of a portfolio of tri-
als), and of robust systems to ensure the conduct and
delivery of clinical trials to the highest quality standards
[2]. These CTUs are key stakeholders in the UK clinical
trials research community, through their involvementntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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Figure 1 Part of the on-line data collection form used in round three.
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and reporting, across a wide range of clinical areas that
encompass an array of trial designs. They are frequently
faced with methodological challenges and many are ac-
tively undertaking research to address those challenges.
The joint National Institute for Health Research (NIHR)
and Medical Research Council (MRC) programme for
methodology research has the dual aims of developing a
high-quality methodology research portfolio and founding
the United Kingdom (UK) as a world leader in methodo-
logical innovation in health research. Led by the MRC, the
NIHR-MRC partnership provided £16 million to establish
a network of regional centres dedicated to trials method-
ology research (Hubs for Trials Methodology Research;
HTMR) in 2008. Located across the UK, the national
HTMR network supports the research community in the
UK by providing scientific leadership in methodology re-
search and investigating new avenues of methodological
research (www.methodologyhubs.mrc.ac.uk).
One HTMR project, led by the North West HTMR,
planned to identify priorities for trials methodology re-
search which would inform the trials methodology re-
search agenda and allow planned research to be placed
into context. This manuscript summarises a Delphi pri-
ority setting exercise involving the Directors of UKCRC
registered CTUs. The Delphi approach allows the an-
onymous opinions of stakeholders to be obtained in a
way that gives equal influence to all who participate, and
avoids an individual participant being overtly influenced
by the opinions of any other participant [3].Table 1 Definition of consensus
Consensus classification Description
Consensus in Consensus that topic should be included as a pr
methodology research
Consensus out Consensus that topic should not be included as
trials methodology research
No consensus Uncertainty about importance of topic as a prior
methodology researchMethods
The Delphi process was used to develop consensus
amongst the Directors of UKCRC registered CTUs.
All 48 Directors were approached through direct
Email contact and asked to participate in each round
of the process, regardless of participation in previous
rounds. A hyperlink to a web based data collection
tool was provided in the Email at each round. A
unique identification number was provided to each
Director so that non-responders could be identified
and sent direct reminder Emails and to allow re-
sponses to be linked between each round. Details of
the methods to be used were described in a protocol
and a summary information sheet provided to Direc-
tors. Due to the on-line format of the survey, comple-
tion of the questionnaire was regarded as consent to
participate.
During round one of the Delphi process, CTU Direc-
tors were asked to provide information about their pro-
fessional experience and list any topics that they felt
were important priorities for trials methodology re-
search. Two members of the research team independ-
ently reviewed and categorised the list of topics from
this round. Disagreements were resolved through discus-
sion and involvement of a third member of the research
team. Topics were split into two separate lists to take
forward to round two: the primary list consisted of
topics which had been identified by more than one
Director, and a secondary list consisted of topics identi-
fied by a single Director.Definition
iority for trials 70% or more participants scoring as 7 to 9 AND < 15%
participants scoring as 1 to 3
a priority for 70% or more participants scoring as 1 to 3 AND < 15% of
participants scoring as 7 to 9
ity for trials Anything else
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Figure 2 Response pattern and characteristics of 48 Clinical
Trials Unit (CTU) Directors at each round of Delphi process.
Tudur Smith et al. Trials 2014, 15:32 Page 3 of 7
http://www.trialsjournal.com/content/15/1/32During round two, all 48 CTU Directors were pro-
vided with the primary list (completion compulsory) and
the secondary list (completion optional) of topics and
asked to assign a score between 1 and 9 to indicate their
opinion about each topic as a research priority. This
used a similar scale to that proposed by the GRADE
group [4], with scores of 1 to 3 indicating that the topic
was not important, scores of 4 to 6 indicating that the
topic was important but not critical, and scores of 7 to 9
indicating that the topic was critical.
During round three, CTU Directors were presented
with a similar web based format to round two but with
additional information displaying the number of re-
sponders in round two, the percentage of Directors that
assigned a particular score to each topic from round
two, and, if relevant, the recipient Director’s individual
score that had been selected in the previous round
(Figure 1). As establishing consensus was the aim, each
Director was asked to consider the responses from the
group of Directors and to provide a revised score if they
considered it appropriate.
A previously suggested [5] approach was used to clas-
sify the consensus status of each topic at the end of
rounds two and three (Table 1). This approach was pre-
defined before the start of round two. Results from
rounds two and three are presented as percentage of re-
sponders, ranked in descending order according to the
critical category (scores 7 to 9).
Results
All 48 UKCRC registered CTU Directors were contacted
between July 2011 and July 2012 and invited to partici-
pate in each of three rounds of the Delphi process. Forty
one CTUs (85%) responded to at least one round; 25
(52%) responded in round one, 32 (67%) responded in
round two, and 24 (50%) responded in round three.
There were 12 (25%) who responded to all three rounds
and 18 (38%) who responded to both round two and
three. The pattern of responses across each round is
shown in Figure 2.
The seven CTUs (15%) which did not respond in any
round did not appear to be atypical compared to
responding CTUs. They covered a range of geographical
areas and clinical specialties which were already largely
represented by the responders.
The 25 CTU Directors responding to round one of the
survey had a median of 20 years’ experience working in
clinical trials (range: 10 to 34 years; interquartile range:
15 to 22 years) and the majority had a statistical
(11 (44%)) or clinical (8 (32%)) background. During
round one, fifty five topics were identified as being im-
portant; 28 topics had been mentioned by more than
one Director (primary list), and 27 topics were each
identified by only one Director (secondary list).For the primary list (topics identified by more than
one Director in round one), consensus was not reached
for any topic during round two (Table 2). However, at
the end of round three there were three topics that
emerged as agreed priorities (consensus in) for method-
ology research: (i) methods to boost recruitment, se-
lected as critical by 83% of responders; (ii) methods to
minimise attrition, selected as critical by 71% of re-
sponders; and (iii) choosing appropriate outcomes to
measure, selected as critical by 71% of responders. In
addition, consensus was reached that ‘radiotherapy study
designs’ should not be a priority for methodology
Table 2 List of topics identified as priorities by more than one Clinical Trials Unit (CTU) Director from round one
(primary list) ordered by round three priority ranks
Round 2 (32 responders) Round 3 (24 responders)
Topic 1 to 3 Scores* 4 to 6 7 to 9 1 to 3 Scores* 4 to 6 7 to 9
% responders % responders Consensus? Rank
Methods to boost recruitment 0.0 43.8 56.3 0.0 16.7 83.3 Consensus in 1
Choosing appropriate outcomes to measure 3.1 28.1 68.8 0.0 29.2 70.8 Consensus in 2
Methods to minimise attrition 6.3 40.6 53.1 0.0 29.2 70.8 Consensus in 2
Methods to minimise bias in trials when
blinding is not possible
0.0 40.6 59.4 0.0 33.3 66.7 4
Pragmatic trials 0.0 56.3 43.8 0.0 45.8 54.2 5
Design and analysis of pilot/feasibility trials 6.3 46.9 46.9 4.2 41.7 54.2 6
Calculating sample size 21.9 31.3 46.9 12.5 33.3 54.2 7
Methods for dealing with missing data 3.1 59.4 37.5 0.0 58.3 41.7 8
Phase II trials 15.6 50.0 34.4 16.7 50.0 33.3 9
Complex interventions 3.1 62.5 34.4 0.0 70.8 29.2 10
Consent in emergency settings 12.5 46.9 40.6 0.0 70.8 29.2 10
Methods for trial monitoring 9.4 65.6 25.0 8.3 62.5 29.2 12
Adjustment for non-adherence to
treatment protocol
6.3 53.1 40.6 4.2 70.8 25.0 13
Stratified medicine design 6.3 56.3 37.5 8.3 66.7 25.0 14
Primary care trials 18.8 56.3 25.0 12.5 62.5 25.0 15
Interim analysis/Data Monitoring issues 9.4 65.6 25.0 0.0 79.2 20.8 16
Adaptive designs 0.0 62.5 37.5 4.2 75.0 20.8 17
Equivalence/non-inferiority trials 12.5 62.5 25.0 12.5 66.7 20.8 18
Dealing with clustering effects 6.3 65.6 28.1 4.2 79.2 16.7 19
Methods for economic analysis 12.5 65.6 21.9 8.3 75.0 16.7 20
Cluster trials 12.5 62.5 25.0 12.5 70.8 16.7 21
Evaluation of electronic data capture methods 28.1 50.0 21.9 20.8 62.5 16.7 22
e-trials 12.5 62.5 25.0 8.3 79.2 12.5 23
Multi-arm Multi-stage (MAMS) designs 12.5 75.0 12.5 12.5 75.0 12.5 24
Stepped wedge designs 15.6 65.6 18.8 16.7 75.0 8.3 25
Randomisation methods 34.4 53.1 12.5 33.3 58.3 8.3 26
Multiplicity 15.6 81.3 3.1 8.3 87.5 4.2 27
Radiotherapy study designs 59.4 34.4 6.3 75.0 20.8 4.2 Consensus out 28
*Scores 1 to 3: topic not important; Scores 4 to 6: topic important but not critical; Scores 7 to 9: topic critical.
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75% of responders.
From the secondary list (topics identified by only one
Director in round one) there was consensus amongst
CTU Directors that ‘low carbon trials’, selected as not
important by 78% of responders, should not be a re-
search priority (Table 3).
Discussion
The Delphi process has been applied to identify topics of
importance and establish consensus for trials methodo-
logical research priorities. ‘Methods to boost recruitmentin trials’ were considered the highest priority, closely
followed by ‘Methods to minimise attrition’ and ‘Choosing
appropriate outcomes to measure’. This group of Direc-
tors of UKCRC registered CTUs also reached consensus
that methodology research into ‘radiotherapy study de-
signs’ and ‘low carbon trials’ should not be priority areas.
Whilst this work is informative in providing broad topic
areas to guide future research, specific research questions
within a particular topic have not been prioritised. A fur-
ther study using similar methodology to the current study
could be undertaken to help identify and prioritise specific
research questions.
Table 3 List of topics identified as priorities by one director from round one (secondary list) ordered by round three priority ranks
Round 2 Round 3 Rank
Topic Number of
responders
1 to 3 Scores* 4 to 6 7 to 9 Consensus? Number of
responders
1 to 3 Scores* 4 to 6 7 to 9 Consensus?
% responders % responders
Surgical trials 30 10.0 43.3 46.7 23 8.7 30.4 60.9 1
Use of routine data 29 17.2 41.4 41.4 23 8.7 39.1 52.2 2
Using previous evidence to inform
design
31 25.8 41.9 32.3 23 13.0 43.5 43.5 3
Strategies of trial management 30 23.3 43.3 33.3 23 17.4 47.8 34.8 4
Assessing potential for and effect of
attrition bias
30 10.0 63.3 26.7 23 4.3 65.2 30.4 5
Non-drug trials 30 23.3 46.7 30.0 22 13.6 59.1 27.3 6
QALYs for children 31 29.0 41.9 29.0 23 21.7 52.2 26.1 7
Calculating the target difference 31 22.6 58.1 19.4 23 13.0 65.2 21.7 8
Patient and public involvement 30 26.7 60.0 13.3 23 26.1 52.2 21.7 9
Strategies for adverse event reporting 30 30.0 50.0 20.0 23 21.7 60.9 17.4 10
Designs in rare diseases 31 12.9 64.5 22.6 23 13.0 73.9 13.0 11
Studies of diagnosis 29 31.0 48.3 20.7 23 39.1 47.8 13.0 12
Methods to adjust for baseline imbalance 31 32.3 51.6 16.1 23 47.8 39.1 13.0 13
Data modelling 30 26.7 56.7 16.7 22 31.8 59.1 9.1 14
Phase IV studies 30 40.0 43.3 16.7 22 54.5 36.4 9.1 15
Prevention studies 30 20.0 60.0 20.0 23 17.4 73.9 8.7 16
Trial reporting issues 28 39.3 50.0 10.7 23 26.1 65.2 8.7 17
Dose–response studies 30 30.0 50.0 20.0 23 34.8 56.5 8.7 18
Methods to measure pain 31 41.9 48.4 9.7 23 47.8 43.5 8.7 19
Low carbon trials 30 70.0 23.3 6.7 out 23 78.3 13.0 8.7 out 20
Eligibility criteria 31 58.1 35.5 6.5 22 63.6 31.8 4.5 21
Patient preference designs/issues 29 20.7 69.0 10.3 23 21.7 73.9 4.3 22
Design of paediatric investigation
plans
30 46.7 43.3 10.0 23 56.5 39.1 4.3 23
Conflict of interest 31 51.6 48.4 0.0 23 65.2 30.4 4.3 24
Database trials 30 33.3 63.3 3.3 23 26.1 73.9 0.0 25
Crossover trials 31 32.3 64.5 3.2 23 39.1 60.9 0.0 26
Incorporating multiple disease/multiple treatment
types into single protocols
30 36.7 50.0 13.3 22 59.1 40.9 0.0 27
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have been applied in clinical research include identifying
gaps and prioritising trials in colorectal cancer [6], defin-
ing national research priorities in bone metastases [7], and
work undertaken by the James Lind Alliance to determine
important questions about treatments where uncertainty
remains [8]. However, to our knowledge no priority setting
exercise using rigorous consensus methods has previously
been undertaken to guide methodological research in clin-
ical trials. Within the growing literature on the elicitation
of opinion and the development of core outcome sets in
clinical trials, the range of consensus methods that have
been applied include expert panel meetings [9], Delphi
surveys [10], Nominal Group Techniques [11], focus
groups [12], individual interviews [13] and individual
questionnaires [14]. The practical difficulties of getting the
CTU Directors together for a face-to-face meeting, and
ensuring that each participant had the opportunity to con-
tribute equally to the consensus process, made the on-line
Delphi approach the preferred method for this particular
priority setting exercise. Further rounds of the Delphi pro-
cess may also have identified additional consensus priorities
but this would have created a further burden for CTU
Directors who are frequently targeted for on-line surveys.
Directors of UKCRC registered CTUs were selected
for this exercise as they have relevant, and established,
expertise in designing and running clinical trials, as well
as being knowledgeable about the current landscape of
methodological research. Ensuring that trials methodo-
logical research focuses on topics that meet the needs of
this group is vital - all too often methodology is devel-
oped without considering the end-user, or the demand
for such research, thus limiting the scope for practical
implementation. It is also worth noting that five out of
eight HTMR Directors are also CTU Directors and partic-
ipated in the Delphi process. Further work with additional
stakeholder groups such as clinical trial investigators,
other methodologists, trial funders and policymakers, al-
beit with an anticipated divergence in perspectives, would
be worthwhile and may show different preferences for
methodological research priorities.
Overall, 41 (85%) of the registered CTUs participated
in at least one of the three completed rounds. However,
whilst this is a good response rate compared to previous
on-line surveys undertaken with this stakeholder group,
only 12 (25%) CTUs responded to all three rounds and
only 18 (38%) responded to both rounds two and three.
The seven CTUs that did not respond to any round cov-
ered a range of geographical areas and clinical specialties
which were largely represented by the responding CTUs.
Several reminders were sent using direct Email contact
and it seems reasonable to assume that lack of time was
the main reason for non-response, rather than substan-
tially different or opposing views.Of course, as has been noted by others, ‘the output
from consensus approaches is rarely an end in itself ’ [3],
but this prioritised list of research topics provides a ro-
bust guide for trials methodology researchers and could
help to focus resources more appropriately. Further-
more, the three identified priority areas are represented
across six working groups that have been established by
the MRC-funded HTMR network (Evidence Synthesis,
Stratified Medicine, Outcomes, Recruitment, Trial Conduct,
Adaptive Designs) to undertake projects on specific issues
in methodology, including the provision of workshops, de-
velopment of guidance papers, and liaison with stake-
holders. Results from this work have been shared with the
joint MRC-NIHR methodology research programme panel
which funds investigator-led and needs-led research on
methods development to underpin a number of areas in-
cluding clinical trials.
Conclusions
Research into methods to boost recruitment in trials,
methods to minimise attrition, and methods for choos-
ing appropriate outcomes to measure are priority topics
for methodological research.
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